Degarelix: a guide to its use in advanced prostate cancer


    loading  Checking for direct PDF access through Ovid

Abstract

Degarelix, a gonadotropin-releasing hormone receptor antagonist, is indicated as an androgen-deprivation therapy in patients with advanced prostate cancer. It effectively induces and maintains suppression of serum testosterone to castrate levels and is generally well tolerated. Adapted from Drugs 2009; 69 (14): 1967-76.[1]

    loading  Loading Related Articles